EVIDENCE FOR BIOCHEMICAL HETEROGENEITY IN SCHIZOPHRENIA - A MULTIVARIATE STUDY OF MONOAMINERGIC INDEXES IN HUMAN POST-MORTAL BRAIN-TISSUE

被引:26
作者
HANSSON, LO
WATERS, N
WINBLAD, B
GOTTFRIES, CG
CARLSSON, A
机构
[1] GOTHENBURG UNIV,DEPT PHARMACOL,MED CHEM UNIT,S-41390 GOTHENBURG,SWEDEN
[2] KAROLINSKA INST,HUDDINGE HOSP,DEPT GERIATR,MOLNDAL,SWEDEN
[3] CENT HOSP MOLNDAL,DEPT CLIN NEUROSCI,PSYCHIAT & NEUROCHEM SECT,MOLNDAL,SWEDEN
关键词
SCHIZOPHRENIA; HETEROGENEITY; MONOAMINES; MULTIVARIATE ANALYSIS;
D O I
10.1007/BF01276538
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
A previously performed post-mortem study comparing monoaminergic indices in the brains of 14 schizophrenic patients and 10 patients with psychosis not diagnosed as schizophrenia, with age-matched control cases without any known neuropsychiatric illness, was re-investigated, using multivariate analysis. The monoaminergic patterns showing up in this analysis suggested the existence of at least two different forms of the disease, both of which could be distinguished from the controls as well as from each other. One of the schizophrenic groups consisted of paranoid cases, and had a relatively mild family history, whereas the other group, mainly consisting of hebephrenic cases, had a severe family history. The former group showed low levels of dopamine and high levels of serotonergic precursor and metabolite, whereas the latter group in some respects tended to show the opposite aberrations. Neuroleptic treatment did not seem to account for the different biochemical profiles, unless one assumes that this treatment can cause completely different monoaminergic aberrations in different individuals. Instead, one could argue that the different biochemical profiles found are characteristic of the disease.
引用
收藏
页码:217 / 235
页数:19
相关论文
共 31 条
  • [1] Atack C.V., Magnusson T., A procedure for the isolation of noradrenaline (together with adrenaline), dopamine, 5-hydroxytryptamine and histamine from the same tissue sample using column of strongly acidic cation exchange resin, Acta Pharmacol Toxicol, 42, pp. 35-57, (1978)
  • [2] Beskow J., Gottfries C.G., Roos B.E., Winblad B., Determination of monoamine and monoamine metabolites in the human brain: post-mortem studies in a group of suicides and in a control group, Acta Psychiatr Scand, 53, pp. 7-20, (1976)
  • [3] Carlsson A., Lindqvist M., Kehr W., Postmortal accumulation of 3-MT in brain, Naunyn Schmiedebergs Arch Pharmacol, 284, pp. 365-372, (1974)
  • [4] Carlsson A., Svennerholm L., Winblad B., Seasonal and circadian monoamine variations in human brains examined post mortem, Acta Psychiatr Scand, 61, pp. 75-83, (1980)
  • [5] Carlsson M., Carlsson A., Interactions between glutamatergic and monoaminergic systems within the basal ganglia — implications for schizophrenia and Parkinson's disease, TINS, 13, pp. 272-276, (1990)
  • [6] Clark M., Cramer R.D., The probability of chance correlation using partial least squares (PLS), Quant Struct-Act Relat, 12, pp. 137-145, (1993)
  • [7] Costall B., Naylor R.J., Neurotransmitter hypothesis of schizophrenia, The psychopharmacology and treatment of schizophrenia, pp. 132-165, (1986)
  • [8] Dunn W.J., Wold S., Pattern recognition techniques in drug design, Comprehensive medicinal chemistry, vol 4, pp. 691-714, (1990)
  • [9] Farley I.J., Price K.S., McCullough E., Deck J.H.N., Hordynski W., Hornykiewicz O., Norepinephrine in chronic paranoid schizophrenia, Science, 200, pp. 456-457, (1978)
  • [10] Gattaz W.F., Gasser T., Beckmann H., Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls, Biol Psychiatry, 20, pp. 360-366, (1985)